Skip to content
Back to meeting Original
Álvaro Pinto· @dralvaropinto · X·· 3 days agoScore45

JNJ-6143

Body

JNJ-6143 phase I study (RIPTAC): good safety profile, with high response rates in a heavily pretreated population with mCRPC. A new mechanism of action has arrived. #ESMO26

39 views · 0 likes · 0 reposts · 0 replies

Source: Álvaro Pinto · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.